August 5, 2008
NeurogesX to Report Second Quarter 2008 Financial Results
SAN MATEO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will report results for its second quarter 2008 on Wednesday, August 13, 2008, after the market closes.
A conference call to review the results will begin at 4:30 p.m. ET (1:30 p.m. PT) on August 13, 2008 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.
To participate in the conference call, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up replay of the conference call will be available beginning August 13, 2008 at 8:00 p.m. ET (5:00 p.m. PT) and ending on August 23, 2008. The replay telephone number is 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 292266.
A live web cast of the call will also be available from the Investor Relations section on the corporate web site at http://www.neurogesx.com/. A web cast replay can be accessed on the corporate web site beginning August 13, 2008 at the same time as the conference call and will remain on the site for one month ending September 13, 2008.
About NeurogesX, Inc.
NeurogesX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' lead product candidate, NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.
NeurogesX, Inc. Stephen Ghiglieri (650) 358-3300 The Ruth Group Investors / Media Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 [email protected] [email protected]
CONTACT: Stephen Ghiglieri of NeurogesX, Inc., +1-650-358-3300; orInvestors, Stephanie Carrington, +1-646-536-7017,[email protected], or Media, Jason Rando, +1-646-536-7025,[email protected], both of The Ruth Group for NeurogesX, Inc.
Web site: http://www.neurogesx.com/